From the databaseWhat the row says.
Every entry follows the same shape: what is happening, the mechanism, and the recommendation.
Scope
Supplement × Supplement
Last verified
June 4, 2026
CautionInsufficient evidence
What is happening. PDA is marketed as an arginate salt and related BPC-157 animal data involve nitric oxide pathways; L-citrulline can raise nitric oxide availability.
Mechanism. Potentially overlapping nitric oxide and vascular effects.
Recommendation. Avoid combining in people with hypotension, nitrate use, or uncontrolled cardiovascular disease.
Stack Score
How it moves the number.
Effect on the composite score
If both L-Citrulline and Pentadeca Arginate (PDA) are in the same stack, this pair applies −5 to your Stack Score (per scored caution row).
The full algorithm, the clamping rules, and four worked stacks are at /methodology/stack-score.
SourcesSources, by evidence tier.
Every claim on this page is cited. PMIDs link straight to PubMed.
Reference material
1- 1Sikiric P et al. BPC 157, L-NAME, L-arginine study. Eur J Pharmacol. 1997.Needs sourceNo link